News Release

Research Article Cites Cleanascite™ to Study Regulatory T Cell Survival in Tumors

MONMOUTH JUNCTION, NJ, February 24, 2020 -- Biotech Support Group reports on a recent research article describing the simplicity and efficiency of their lipid clearance sample preparation technology for studying cell response factors associated with intratumoral Treg cells. The citation is: 

Wang, Haiping, et al. "CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors." Nature Immunology (2020): 1-11.

Depleting regulatory T cells (Treg cells) to counteract immunosuppressive features of the tumor microenvironment (TME) is an attractive strategy for cancer treatment. However, systemic impairment of their suppressive function limits its therapeutic potential. Elucidating approaches that specifically disrupt intratumoral Treg cells is direly needed for cancer immunotherapy. The use of Cleanascite™ helped demonstrate that intratumoral Treg cells increase lipid metabolism and CD36 expression. The article states “cancer cell-conditioned medium … was treated with Cleanascite reagent (Biotech Support Group) before Treg cell culture at a volume ratio of 1:5 according to the manufacturer’s instructions.” The study concludes that CD36 targeting elicited additive antitumor responses with anti-programmed cell death protein 1 therapy. The findings uncover the unexplored metabolic adaptation that orchestrates the survival and functions of intratumoral Treg cells, and the therapeutic potential of targeting this pathway for reprogramming the tumor microenvironment.

“Its rewarding to see another reference whereby Cleanascite™ helped to identify a characteristic feature of the tumor microenvironment. As Cleanascite™ is an aqueous suspension product without harmful solvents, one can use it to challenge cells for responsiveness. This ultimately helps researchers decide whether or not lipids impart characteristic changes in cells, such as the relative expression of membrane receptors like CD36. This information will hopefully help our understanding of how to reprogram the tumor microenvironment for therapeutic benefit.” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

To download whitepaper entitled “Cleanascite™ - Lipid Removal and Cell Response Applications”, visit:

http://www.biotechsupportgroup.com/v/vspfiles/templates/257/pdf/CleanasciteCellResponseReferenceApplications121218.pdf

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com/. 

Contact: Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com